

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



友芝友生物製藥

WUHAN YZY BIOPHARMA CO., LTD.

武漢友芝友生物製藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2496)

INSIDE INFORMATION

GRANT OF LISTING APPROVAL BY THE STOCK EXCHANGE FOR THE H SHARE FULL CIRCULATION OF THE COMPANY

This announcement is made by Wuhan YZY Biopharma Co., Ltd. (the “**Company**”) under Rule 13.09(2)(a) of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

References are made to the announcements of the Company dated May 12, 2025 and January 26, 2026 (the “**Announcements**”) in relation to the proposed H Share Full Circulation. Unless otherwise defined, capitalised terms used herein have the same meanings as those defined in the Announcements.

GRANT OF LISTING APPROVAL BY THE STOCK EXCHANGE

The Board is pleased to announce that the Company has received the approval granted by the Stock Exchange dated February 4, 2026, for the listing of and permission to deal in 68,010,299 H Shares (the “**Converted H Shares**”), representing the total number of the unlisted shares of the Company (the “**Unlisted Shares**”) to be converted under the Conversion and Listing.

SHAREHOLDING STRUCTURE

The Conversion and Listing will involve 9 participating shareholders (the “**Participating Shareholders**”) holding an aggregate of 68,010,299 Unlisted Shares, comprising 61,140,555 unlisted domestic shares of the Company (the “**Unlisted Domestic Shares**”) and 6,869,744 unlisted foreign shares of the Company (the “**Unlisted Foreign Shares**”). The number of Converted H Shares held by the Participating Shareholders represents approximately 35.08% of the total issued shares of the Company as at the date of this announcement.

Upon completion of the Conversion and Listing, the shareholding percentages of the Participating Shareholders in the Company are set out below.

Name of the Participating Shareholders	Number of Converted H Shares (shares)	Approximate percentage of the total issued shares of the Company upon completion of the H Share Full Circulation (%)
<i>Holders of Unlisted Foreign Shares</i>		
Dr. Zhou Pengfei	6,869,744	3.54
<i>Holder of Unlisted Domestic Shares</i>		
Dr. Yuan Qian	20,399,933	10.52
Wuhan Caizhi Investment Management Partnership (Limited Partnership) (武漢才智投資管理合夥企業(有限合夥))	16,792,707	8.66
Dr. Zhou Hongfeng	10,199,921	5.26
Nanjing Caizhi No. 2 Enterprise Management Partnership (Limited Partnership) (南京才智二號企業管理合夥企業(有限合夥))	5,810,206	3.00
Nanning Huiyou Xingyao Equity Investment Fund Partnership (Limited Partnership) (南寧匯友興曜股權投資基金合夥企業(有限合夥))	3,447,526	1.78
Gongqingcheng Huiyou Xingyao Phase II Equity Investment Partnership (Limited Partnership) (共青城匯友興曜二期股權投資合夥企業(有限合夥))	1,611,513	0.83
Nanjing BGI Co-win Fund I Venture Capital Enterprise (Limited Partnership) (南京華大共贏一號創業投資企業(有限合夥))	1,919,166	0.99
Zhuhai Shengyi Investment Partnership (Limited Partnership) (珠海盛溢投資合夥企業(有限合夥))	959,583	0.50
Total	68,010,299	35.08

Note: In this announcement, any discrepancies between totals and sums of figures listed are due to rounding.

The shareholding structure of the Company as at the date of this announcement and immediately upon completion of the Conversion and Listing is set out below:

Type of Shares	As at the date of this announcement		Immediately upon completion of the Conversion and Listing	
	Number of Shares (shares)	Approximate percentage (%)	Number of Shares (shares)	Approximate percentage (%)
Unlisted Domestic Shares	75,510,642	38.95	14,370,087	7.41
Unlisted Foreign Shares	6,869,744	3.54	—	—
H Shares	111,468,814	57.50	179,479,113	92.59
Total	<u>193,849,200</u>	<u>100</u>	<u>193,849,200</u>	<u>100</u>

The Company shall complete the relevant conversion and trading procedures in respect of the Converted H Shares and will make further announcement(s) on the progress of the H Share Full Circulation and the Conversion and Listing in accordance with the requirements under the Listing Rules and applicable laws, as and when appropriate.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares and other securities of the Company.

By order of the Board
Wuhan YZY Biopharma Co., Ltd.
Dr. Zhou Pengfei
*Chairman of the Board, Executive Director
and Chief Executive Officer*

Wuhan, PRC, February 4, 2026

As at the date of this announcement, the Board comprises Dr. Zhou Pengfei and Mr. Wen Zhicheng as executive directors; Dr. Yuan Qian, Dr. Zhou Hongfeng, Mr. Pang Zhenhai, Dr. Hui Xiwu and Mr. Xie Shouwu as non-executive directors; and Dr. Cheng Bin, Ms. Fu Lili, Dr. Deng Yuezhen and Dr. Chen Bin as independent non-executive directors.